Sugi Predict

Sugi Predict / Compounds / SCHEMBL5043957

SCHEMBL5043957

SCHEMBL5043957

Cc1ccc(CSc2cc(C(O)C#Cc3ccc(C(=O)NO)cc3)cc3c2C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 10/20 0.37
▸ HDAC1 Q13547 10/20 0.37
▸ HDAC2 Q92769 7/20 0.37
▸ HDAC3 O15379 6/20 0.37
▸ HDAC8 Q9BY41 6/20 0.37
▸ HDAC4 P56524 5/20 0.37
▸ HDAC7 Q8WUI4 5/20 0.37
▸ HDAC10 Q969S8 5/20 0.37
▸ HDAC11 Q96DB2 5/20 0.37
▸ HDAC9 Q9UKV0 5/20 0.37
▸ HDAC5 Q9UQL6 5/20 0.37
▸ RXRA P19793 1/20 0.37
▸ HNF4A P41235 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ NCOR2 Q9Y618 3/20 0.33
▸ POLB P06746 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ CYP3A4 P08684 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047103 0.93 HDAC6 (0.41) HDAC6HDAC1HDAC2HDAC3HDAC8
SCHEMBL5048405 0.92 KMT2A (0.37) HNF4AMEN1KMT2APOLBHPGD
SCHEMBL5047234 0.91 HDAC1 (0.39) HDAC6HDAC1HDAC2HDAC3HDAC8
SCHEMBL5050769 0.91 RARB (0.43) RXRAHNF4ACYP3A4CYP26A1RARA
SCHEMBL5043970 0.90 HNF4A (0.34) RXRAHNF4AMEN1KMT2ASMN1; SMN2
SCHEMBL5044050 0.87 ACACB (0.33) RXRAHNF4ASMN1; SMN2CYP3A4LMNA
SCHEMBL5049648 0.85 LMNA (0.36) HDAC6HDAC1MEN1KMT2AHPGD
SCHEMBL5048441 0.84 HDAC6 (0.39) HDAC6HDAC1HDAC2HDAC3HDAC8
SCHEMBL5044062 0.83 HDAC1 (0.41) HDAC6HDAC1HDAC2HDAC3HDAC8
SCHEMBL5047206 0.83 MAPT (0.35) RXRAMEN1KMT2APOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 — — US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 — — US claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 — — US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG HDAC6 2024/4885HDAC1 675/4885HDAC2 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.